Synthesized once, rediscovered decades later
MDMA (3,4-methylenedioxymethamphetamine) was first synthesized by chemist Anton Köllisch at the pharmaceutical company Merck in 1912 — the specific reason it was made and whether it was seriously explored at the time remains genuinely unclear from surviving records, and the popular claim that it was designed as an appetite suppressant is disputed rather than confirmed. It sat largely unexamined for over sixty years until Alexander "Sasha" Shulgin, an influential chemist, resynthesized it in the 1970s and introduced it to psychotherapist Leo Zeff. Zeff was reportedly convinced enough by its effects to come out of retirement, going on to introduce MDMA — legally, since it wasn't yet scheduled — to hundreds of other therapists over the following years, who used it, entirely outside any formal clinical trial structure, as an aid to opening emotional communication in individual and couples therapy.
From therapist's tool to Schedule I in under a decade
That quiet clinical use didn't stay quiet. By the mid-1980s, MDMA had become a recreational phenomenon under the name "Ecstasy," and the DEA moved to schedule it in 1985 specifically to curb its spreading recreational use — placing it in Schedule I, the same category as heroin, and legally ending the informal therapeutic practice that had been happening in parallel. Recreational use exploded alongside the global rave and EDM scene from the late 1980s through the 2000s, cementing its cultural identity as a nightlife drug for a generation of users who mostly had no idea it had started its modern life inside a therapist's office.
The long road back to the FDA
Research into MDMA-assisted psychotherapy for PTSD resumed in the early 2000s, championed for decades by the nonprofit MAPS (Multidisciplinary Association for Psychedelic Studies). Between 2004 and 2017, six Phase 2 trials showed significant reductions in PTSD symptoms among participants, and the FDA granted the treatment Breakthrough Therapy designation — a strong signal of regulatory confidence. Then, in August 2024, the FDA formally rejected the New Drug Application, following an advisory committee vote against approval that cited concerns about study design (including the practical difficulty of a genuinely "blinded" trial when participants can often tell whether they received MDMA or a placebo based on its effects alone) and cardiovascular safety data. In August 2026 the trade outlet Psychedelic Alpha reported that the therapy's developer — Lykos Therapeutics, renamed Resilient Pharmaceuticals in 2025 — had resubmitted the application without running a new Phase 3 trial, two years after the initial rejection; the company had not publicly confirmed it, and the outcome is still genuinely pending.
MDMA-assisted therapy has the most extensive real clinical trial history of any drug in this category's "still seeking approval" group — and also the most cautionary tale about how much rides on trial design, not just whether a drug works.
What the drug actually does, and the real dangers
MDMA produces a distinctive combination of stimulant energy and strong feelings of emotional openness, empathy, and closeness to others — the specific combination that made it attractive to therapists is largely the same combination that made it attractive to ravers.
Overheating is the classic rave-context danger — and the standard advice around it is more nuanced than "drink water." MDMA increases body temperature and, combined with intense dancing in hot, crowded spaces, can cause dangerous hyperthermia. But the common harm-reduction slogan oversimplifies the fix: some MDMA-related deaths have resulted specifically from drinking too much water in a short period, causing a dangerous drop in blood sodium (hyponatremia) rather than dehydration. The actual guidance from harm-reduction organizations is moderate fluid intake (sipping roughly a pint, about 500 ml, per hour while dancing and less while resting; the UK's FRANK service advises not drinking more than that), regular cooling breaks, and never chugging large volumes of water at once.
Serotonin syndrome risk with certain combinations. MDMA affects serotonin directly, and combining it with SSRIs, MAOIs, or other serotonergic medications and drugs (including the ayahuasca covered earlier in this category) carries a real risk of serotonin syndrome, a potentially dangerous reaction.
Adulteration is the single biggest real-world risk today. Illicit "Molly" or "Ecstasy" sold on the street or at events frequently contains little or no actual MDMA — synthetic cathinones ("bath salts"), methamphetamine, and increasingly fentanyl have all been found in products sold as MDMA, since illicit production has no quality control whatsoever. This is arguably the most important practical fact in this piece: a substantial share of "MDMA" harm is actually harm from an entirely different, unlabeled substance.
Neurotoxicity concerns are real but were significantly overstated in 1990s-2000s media coverage. Some research has raised legitimate questions about serotonergic effects from heavy, frequent use, but the more alarmist "Ecstasy causes holes in your brain" framing common in earlier public messaging oversold the certainty and severity of the evidence available. The honest current position: heavy, frequent use likely carries some real risk to serotonergic function; occasional, moderate use in tested, unadulterated form appears to carry substantially less.
Not classically physically addictive, but tolerance builds fast. Repeated use in close succession rapidly diminishes MDMA's characteristic effects — a pattern Shulgin himself documented — which naturally discourages frequent redosing, though psychological dependence patterns can still develop.
Try this
If you or anyone you know uses MDMA recreationally, get it tested first — reagent test kits and services (including organizations like DanceSafe, which also operates at many festivals) can identify whether a substance is actually MDMA or something else entirely, which current evidence suggests is the single largest real-world risk factor.
The takeaway
MDMA was synthesized in 1912, then quietly used by therapists to aid emotional communication in the late 1970s and early '80s — legally, before recreational use exploded and led to its 1985 Schedule I classification. Its return toward FDA approval has been genuinely dramatic: strong Phase 2 trial results and Breakthrough Therapy status, followed by a 2024 rejection over trial-design and safety concerns, with a resubmitted application reported in August 2026 and still pending. Its real dangers include hyperthermia (and, less intuitively, dangerous overhydration from over-correcting for it), serotonin syndrome in certain combinations, and — the single biggest practical risk today — a street supply frequently adulterated with entirely different, unlabeled substances.
Try this: if MDMA use is part of your or someone else's life, prioritize reagent testing the actual substance — adulteration, not MDMA itself, is the leading real-world risk.
Sources & Further Reading
Sources
- MDMA's 1912 synthesis, Shulgin's 1970s rediscovery, and its use in underground therapy before 1985 scheduling reflect documented pharmacological and drug-policy history.
- MDMA-assisted therapy's clinical trial history and 2024 FDA rejection reflect published FDA and pharmaceutical-industry reporting; the resubmission: Psychedelic Alpha, "Two Years After Rejection, Resilient Quietly Refiles MDMA for PTSD Application" (August 2026), and MAPS's response (10 August 2026).
- Hyponatremia and hyperthermia risk, and current harm-reduction fluid-intake guidance, reflect published harm-reduction and clinical literature.
- Adulteration prevalence in the illicit MDMA/"Molly" supply reflects published drug-checking service data (including DanceSafe testing results).
- Neurotoxicity research context reflects the broader clinical and neuropharmacological literature on MDMA.
Go deeper
- 🌐 DanceSafe.org — reagent testing information and current adulterant alerts
- 🌐 Search "MDMA PTSD FDA resubmission 2026" for the current regulatory status
- 🌐 Related pieces in this library: Ayahuasca, this category, for the shared serotonin syndrome/MAOI interaction risk